SCHEMBL3898574

SCHEMBL3898574

CCCCCC(CN(O)C=O)C(=O)NS(=O)(=O)c1ccc(C(=O)OCCC)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 7/20 0.45
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MMP12 P39900 1/20 0.41
ESR1 P03372 2/20 0.40
TSHR P16473 2/20 0.40
CHRM1 P11229 1/20 0.40
SLC6A2 P23975 1/20 0.40
KDR P35968 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
NR1H2 P55055 1/20 0.39
RNASEL Q05823 1/20 0.39
STS P08842 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3903242 0.91 BMP1 (0.49) BMP1ALDH1A1MMP12TSHRCYP1A2
SCHEMBL3895773 0.85 ALDH1A1 (0.47) BMP1ALDH1A1MMP12TSHRTDP1
SCHEMBL3898521 0.84 BMP1 (0.51) BMP1ALDH1A1MMP12
SCHEMBL3904165 0.84 BMP1 (0.46) BMP1ALDH1A1SMN1; SMN2MMP12TSHR
SCHEMBL3900004 0.84 BMP1 (0.55) BMP1MMP12
SCHEMBL3900625 0.83 BMP1 (0.46) BMP1MMP12
SCHEMBL3911104 0.82 BMP1 (0.56) BMP1MMP12
SCHEMBL3897011 0.82 BMP1 (0.52) BMP1MMP12
SCHEMBL3898472 0.80 BMP1 (0.51) BMP1
SCHEMBL3900792 0.78 TARS1 (0.49) BMP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615629-B1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-03-18 EP claimed
US-7375120-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-05-20 US claimed
US-20060229341-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2006-10-12 US claimed
EP-1615629-B1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-03-18 EP disclosed
US-7375120-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-05-20 US disclosed
EP-1615629-A4 PEPTIDE DEFORMYLASE INHIBITORS CHRISTENSEN SIEGFRIED B IV (US) 2007-02-28 EP disclosed
US-20060229341-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2006-10-12 US disclosed
EP-1615629-A1 PEPTIDE DEFORMYLASE INHIBITORS Christensen, Siegfried B. IV (US) 2006-01-18 EP disclosed
WO-2004098584-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229341-A1 Peptide deformylase inhibitors PDF, PEPD, DPEP1 BMP1 1590/4885ALDH1A1 4302/4885SMN1; SMN2 2654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.